An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that
has caused the recent coronavirus disease (COVID-19) global pandemic. The current …
has caused the recent coronavirus disease (COVID-19) global pandemic. The current …
Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines
ABSTRACT Introduction The Coronavirus Disease 2019 (COVID-19) pandemic has caused
devastating human and economic costs. Vaccination is an important step in controlling the …
devastating human and economic costs. Vaccination is an important step in controlling the …
Efficacy and safety of the RBD-dimer–based COVID-19 vaccine ZF2001 in adults
L Dai, L Gao, L Tao, SR Hadinegoro… - New England journal …, 2022 - Mass Medical Soc
Background The ZF2001 vaccine, which contains a dimeric form of the receptor-binding
domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an …
domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an …
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
To combat future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health …
and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health …
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer …
Background Vaccination has helped to mitigate the COVID-19 pandemic. Ten traditional and
novel vaccines have been listed by the World Health Organization for emergency use …
novel vaccines have been listed by the World Health Organization for emergency use …
A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
S Wang, CY Wang, HK Kuo, WJ Peng… - Emerging Microbes & …, 2022 - Taylor & Francis
The development of safe and effective vaccines to respond to COVID-19 pandemic/endemic
remains a priority. We developed a novel subunit protein-peptide COVID-19 vaccine …
remains a priority. We developed a novel subunit protein-peptide COVID-19 vaccine …
[HTML][HTML] ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
Prime-boost regimens for COVID-19 vaccines elicit poor antibody responses against
Omicron-based variants and employ frequent boosters to maintain antibody levels. We …
Omicron-based variants and employ frequent boosters to maintain antibody levels. We …
Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines
J Zhou, Z Liu, G Zhang, W Xu, L Xing… - Journal of Medical …, 2023 - Wiley Online Library
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
variants with high transmission rates and striking immune evasion have posed a serious …
variants with high transmission rates and striking immune evasion have posed a serious …
Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine
JF Lovell, YO Baik, SK Choi, C Lee, JY Lee, K Miura… - BMC medicine, 2022 - Springer
Background Numerous vaccine strategies are being advanced to control SARS-CoV-2, the
cause of the COVID-19 pandemic. EuCorVac-19 (ECV19) is a recombinant protein …
cause of the COVID-19 pandemic. EuCorVac-19 (ECV19) is a recombinant protein …
Mucosal SARS-CoV-2 nanoparticle vaccine based on mucosal adjuvants and its immune effectiveness by intranasal administration
L Xiao, W Yu, L Shen, W Yan, J Qi… - ACS Applied Materials & …, 2023 - ACS Publications
SARS-CoV-2 is a respiratory virus that causes significant threats to human health. Mucosal
immunity provides a first-line defense to prevent the infection of SARS-CoV-2 in the …
immunity provides a first-line defense to prevent the infection of SARS-CoV-2 in the …